Eli Lilly and Novo Nordisk are developing amylin-based obesity drugs to complement GLP-1 medicines, as Lilly reported Phase 2 data showing eloralintide plus tirzepatide led to 23.3% weight loss at 48 weeks.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
